Gold surged 65% in 2025 — its strongest performance in nearly half a century — as retail and institutional investors piled in ...
Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback